Proteome Sciences PLC License Agreement Extension (5322J)
03 April 2018 - 4:01PM
UK Regulatory
TIDMPRM
RNS Number : 5322J
Proteome Sciences PLC
03 April 2018
3 April 2018
Proteome Sciences plc
("Proteome Sciences" or the "Company")
License Agreement Extension with Thermo Fisher Scientific
Electrophoretics Ltd, a wholly owned subsidiary of Proteome
Sciences plc, is pleased to announce that it has signed an
amendment to the exclusive License and Distribution Agreement with
Pierce Biotechnology Inc., a part of Thermo Fisher Scientific Inc.,
extending the current license to include intellectual property
relating to a new class of higher-plex TMT(R) reagents currently in
development. Such higher-plex technology represents the next phase
in the evolution of isobaric tagging and will enable further
advances in the efficiency and utility of mass spectrometric
protein analyses.
Jeremy Haigh, Chief Executive Officer of Proteome Sciences plc,
commented: "We are delighted to extend our successful and exclusive
collaboration with Thermo Fisher Scientific through which TMT(R)
has become the market leader and established standard for
multiplex, quantitative proteomic experiments. The development of
higher-plex TMT(R) reagents has been a long-standing objective for
Proteome Sciences and we look forward to continuing our partnership
with a recognised world leader in serving science and
innovation."
For further information:
Proteome Sciences plc
Jeremy Haigh, Chief Executive Tel: +44 (0)20 7043
Officer 2116
Ian Pike, Chief Scientific
Officer
finnCap Limited (Nominated Adviser & Broker)
Geoff Nash/James Thompson Tel: +44 (0)20 7220
Abigail Wayne (Broking) 0500
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering
high sensitivity, proprietary technologies and workflows for
mapping cell signalling pathways (SysQuant(R) ) and for the
discovery, validation and assay development of protein biomarkers
(TMTcalibrator(TM) ). The company has its headquarters in London,
UK, with laboratory facilities in Frankfurt, Germany from where the
PS Biomarker Services(TM) division provides outsourced proteomics
services and proprietary biomarker assays to biopharmaceutical and
diagnostics companies and to academia.
Proteome Sciences has patented several novel protein biomarkers
for diagnostic and treatment applications in important areas of
human therapeutics such as cancer, stroke and Alzheimer's disease,
and these are available for license.
This announcement contains inside information for the purpose of
Article 7 of EU Regulation 596/2014
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRLLFSRSLIFIIT
(END) Dow Jones Newswires
April 03, 2018 02:01 ET (06:01 GMT)
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2024 to May 2024
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From May 2023 to May 2024